benefits of glp-1 Cardiovascular glucagon-like peptide-1 receptor agonists Benefits and drawbacks of GLP-1

They also decrease obesity-linked cancer risks by roughly 7%

They include a sluggish metabolism, vitamin and mineral deficiencies, and even resistance to insulin

To identify beneficiaries with peripheral arterial disease (PAD), we used ICD-9 diagnosis codes for PAD identified by either Hirsh et al (August 2008) or Jaff et al (July 2010) in their analyses of peripheral arterial disease among Medicare beneficiaries

Real GLP-1 receptor agonists like semaglutide and tirzepatide are prescription medications backed by massive clinical trials involving tens of thousands of participants

The potential is real, but we need bigger, longer trials before this area becomes a clinical reality